Tirzepatide Sleep Apnea: SURMOUNT-OSA Results

What did the tirzepatide sleep apnea trials find? In the two SURMOUNT-OSA phase 3 trials, adults with obesity and moderate-to-severe obstructive sleep apnea had about 20 to 24 fewer breathing interruptions per hour of sleep than placebo after 52 weeks. These results apply to that population and the prescription formulation studied, not to research vials.

This original FirstLabs editorial review was updated November 3, 2026. It is educational information, not medical advice, a dosing guide or a recommendation for personal use. FirstLabs catalogue materials are for laboratory research only, not human or veterinary use.

Obstructive sleep apnea and the AHI

Obstructive sleep apnea (OSA) means the upper airway repeatedly narrows or closes during sleep. Severity is usually measured with the apnea-hypopnea index (AHI), the number of breathing pauses or shallow-breathing events per hour. Excess body fat is a major risk factor, which is why researchers tested a weight-reducing medicine.

How SURMOUNT-OSA was designed

Malhotra and colleagues ran two double-blind, randomized, placebo-controlled phase 3 trials for 52 weeks in adults with obesity and moderate-to-severe OSA. Trial 1 enrolled people not using positive airway pressure (PAP) therapy; trial 2 enrolled people using PAP. Mean baseline AHI was 51.5 and 49.5 events per hour, and mean BMI was about 39.

Results after 52 weeks

Trial 1 (no PAP): AHI fell by 25.3 events per hour with tirzepatide versus 5.3 with placebo, a difference of −20.0.
Trial 2 (using PAP): AHI fell by 29.3 versus 5.5, a difference of −23.8.

All pre-specified key secondary endpoints also improved compared with placebo, including body weight, hypoxic burden, patient-reported sleep impairment, hs-CRP and systolic blood pressure. The most common side effects were gastrointestinal and mostly mild to moderate.

What the trials do not show

A lower AHI is not the same as a cure; many participants still had measurable sleep apnea. The trials lasted 52 weeks and were not designed to show fewer heart attacks or strokes. They do not show that tirzepatide replaces PAP therapy, and they were funded by Eli Lilly.

Tirzepatide and sleep apnea: frequently asked questions

How much did tirzepatide reduce sleep apnea events?

About 20 to 24 fewer events per hour than placebo at 52 weeks, depending on the trial.

Were participants also using CPAP?

In one of the two trials, yes. The other trial enrolled people not using PAP therapy.

Do these results apply to research vials?

No. They apply to the prescription formulation in a supervised trial population.

Laboratory documentation is a separate question

Evidence about tirzepatide in a clinical study does not establish that a FirstLabs vial is equivalent to the studied formulation. A certificate of analysis describes the submitted sample, not medical suitability or regulatory authorization. HPLC purity does not by itself establish quantity, sterility, endotoxin control or a match to current stock.

For laboratory records, verify exact identity and labelled size, analytical methods, measured quantity, sample identifiers and any available lot-to-stock documentation. A laboratory task ID is not automatically a manufacturing lot. Keep missing reports and adverse results visible rather than borrowing evidence from another size.

Related reading: Tirzepatide heart failure trial, stopping versus continuing tirzepatide and tirzepatide clinical evidence. See the Tirzepatide research catalogue for laboratory sizes. The cover is an illustrative sleep-lab scene.

Read our COA verification checklist, published laboratory reports and Canadian regulation overview for these distinctions.

Primary sources and editorial scope

FirstLabs is a research-material supplier with a commercial interest in the compounds discussed, not a licensed pharmacy or an independent medical authority. Results belong to their original study populations, formulations and endpoints. No personal outcome, treatment protocol or authorization of catalogue products is implied.

Tirzepatide and Sleep Apnea: SURMOUNT-OSA Trial Results